Cytogen

At a glance

Cytogen filed 54 disclosures in the last 12 months, including 10 5% holder, 5 insider, 1 contract, 1 issuance and 1 m&a. The most recent key filing was on Oct 12: A major holder's stake fell from 44.42% to 41.30% (gift).

Revenue for 2025 was ₩26.1B, up 138.8% on 2024. It made an operating loss of ₩8.2B. Debt was 73% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩13.2B and operating loss of ₩2.7B.

The 2025 annual report lists 39 employees with an average tenure of 3.3 years and average pay of ₩64.4M. Its 9 directors and auditors were paid ₩87M each on average. It paid no cash dividend for 2025. 캔디엑스홀딩스 유한회사 and related parties held 31.96% at year end.

Of 2 recent 5%+ holder reports, 0 raised and 1 cut a stake; the largest stake reported was 41.30% on Oct 12.

From the 2025 annual report

Staff: 39 (21 men, 18 women), of whom 4 on fixed-term contracts. Total pay for the year: ₩2.7B. Directors and auditors: 9, paid ₩772.2M in total.

No cash dividend was paid for 2025.

Largest shareholder

캔디엑스홀딩스 유한회사 holds 31.96%; with 0 related parties the group holds 31.96% of common shares at year end.

Auditor: 이촌회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports